Apollo Health Ventures

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

How many of us will enjoy a healthy lifespan of over 100 years old in the coming era of longevity? Why must people with disabilities have life limitations? Human Augmentation has great potential to extend our health and lifespan to overcome limitations caused by ageing and disabilities, in order to create the world where everyone can lead a fulfilling life.

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

We are dedicated team of experienced investors who help to enable groundbreaking work by investing in and fostering companies and technologies that advance the future of health. Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care Established by UNC REX Healthcare in 2012 as part of its commitment to innovation Partners with emerging companies throughout North Carolina and the U.S. Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network

Positron Ventures helps and funds Europe-based scientist-entrepreneurs who are pursuing moonshots for (planetary) health. We invest in scientist-entrepreneurs working on a breakthrough in their field, across the natural sciences. We back teams from day one in their pursuit of solving a major global challenge. We do this with pre-seed investments and, wherever needed, support across all aspects of building a company. If you are looking for funding, check out our investment criteria and shopping list, and our view on when to engage. If you think there might be a match, contact us at startups@positron.vc. Scientists who have not yet spun out a company but are interested in doing so, please check our scientist resources.

We build breakthrough biotechnology companies. Exceptional entrepreneurs and scientists translate innovation into novel medicines. We play the long game with urgency. Patience, discipline, and vision to bring new transformational medicines to life. We are relentless truth-seekers. Our seed-led investment model uncovers the most promising opportunities. We understand the power of community. We prioritize a collaborative, science-first, patient-centric culture.